Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
Q3 2025 vs. Q2 2025
How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 7 | 9 | +2 |
| Shares | 3.08M | 3.37M | +289.7K (+9.4%) |
| Value | $383.1K | $1.09M | +$708.6K (+184.9%) |
New holders (3)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Boothbay Fund Management, LLC | 357,447 | $850.7K | 0.02% |
| Clear Street Group Inc. | 120 | $10 | 0.00% |
| Bank of America Corp | 101 | $8 | 0.00% |
Sold out (1)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Zazove Associates LLC | 65,456 | $6.21K |